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Objective: The aim of this study was to analyze the prognostic factors correlated with survival
of  patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal
do  Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological
proﬁle.
Methods: The overall survival and disease-free survival were statistically evaluated using
the  Kaplan–Meier method, the log-rank test and multivariate evaluation by Cox regression
analysis.
Results: The study population was predominantly younger than 60 years old (81,6%), had
intermediate cytogenetic risk (40.8%), in ﬁrst complete remission after induction chemother-
apy  (46.9%), with a white blood count at diagnosis of less than 30 × 109/L (57.1%) and de novo
acute  myeloid leukemia (62.2%). Survival curves showed that better prognosis was related
to  age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good pro-
gnostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and
white blood cell count at diagnosis of less than 30 × 109/L (median survival: 23.6 months; p-
value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the
median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4
months for M4, M5, M6, and M7 (p-value = 0.0288).
Conclusion: Prognostic factors strongly inﬂuenced patient survival, as well as guided treat-
ment. Moreover, these factors were consistent with the available literature adjusted for the
population in question.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Hospital de Clínicas da Universidade Fede
0060-900 Curitiba, PR, Brazil.
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Introduction
Neoplastic diseases were historically associated with econom-
ically developed countries. For approximately four decades,
however, this situation has changed and a lot of the onus is
observed in developing countries. Infectious diseases are not
the main cause of death anymore and cancer has acquired a
greater dimension, becoming a global public health problem.1
Hematological malignancies represent 7% of new cancer
cases each year.2 According to The Brazilian National Can-
cer Institute, it has been estimated that there were 4570 new
cases in men  and 3940 in women in 2012. Acute myeloid
leukemia (AML) is the most common acute leukemia in adults
and accounts for approximately 80% of the cases in this group,
with an annual incidence of 2.7 cases per 100,000 population.3
AML  is a relatively rare disease with high heterogeneity in
the affected population in terms of morphology, immunophe-
notype, cytogenetics and molecular abnormalities. It is a
clonal proliferation of myeloid precursors, the result of genetic
and epigenetic alterations that disrupt self-renewal, prolif-
eration and differentiation of cells, with accumulation of
leukemic blasts or immature cells in the bone marrow.4 The
clinical outcome is extremely variable, with survival from a
few days to a deﬁnitive cure of some clinical and biological
aspects, which is useful in predicting outcomes.4–6
Several clinical features can predict complete remission
and the event-free survival (EFS) of these patients. The most
important prognostic factors regarding adverse clinical pre-
sentations, include age, cytogenetic abnormalities, secondary
leukemia, white blood cell (WBC) count and complete remis-
sion after the ﬁrst induction.5,7
The cases can be morphologically subclassiﬁed according
to the French-American-British (FAB) system. This form of
organization does not provide additional prognostic informa-
tion, but it is important to systematize acute promyelocytic
leukemia, a biological and clinical variant of AML, classi-
ﬁed as AML  M3  in the FAB system, currently called acute
promyelocytic leukemia with t(15,17)(q24.1,q21.1), and PML-
RARA, in the World Health Organization (WHO) classiﬁcation
system.8–10
Brazil has peculiarities regarding its territorial dimensions,
with important regional differences in the occurrence of the
disease and distribution of associated risk factors and so local
information is extremely important for analytical exploration
of this malignancy.
Prospects for patients have improved over the last 30 years,
but despite signiﬁcant progress, the treatment outcome is
variable and frequently suboptimal. More  than half of young
and adult patients, and about 90% of the deaths of over 60-
year-old patients in this population are disease related.5,6,11,12
This study shows the indispensability of registries with
standardized, up-to-date and representative information, due
the considerable variations between populations in relation to
survival and epidemiological characteristics which can predict
treatment outcome.The aim of this study was to analyze the inﬂuence of
prognostic factors described in the literature correlated with
survival of patients with acute myeloid leukemia treated
between 2003 and 2009 at the Hematology and Oncologyr. 2 0 1 5;3 7(1):21–27
Service of the Hospital de Clínicas, Universidade Federal do
Paraná (HC-UFPR), Brazil, as well as to trace the clinical and
epidemiological proﬁle of the patients.
Methods
This retrospective analytical study was conducted at HC-UFPR
after being approved by the Ethics Committee of the hospital.
The study population was selected using records from the
Computer Information Service and the Hospital Cancer Reg-
istry of HC-UFPR using the following inclusion criteria: the
International Classiﬁcation of Diseases (ICD) of AML, older
than 15 years old and diagnosis between January 2003 and
December 2009. The initial patient set consisted of patients,
predominantly treated with combined induction chemother-
apy using cytarabine and daunorubicin (the so-called “7 + 3”
regimen) for non-M3 leukemias, and all-trans retinoic acid
(ATRA) alone or combined with an anthracycline for the M3
subtype.
Patients who were not treated exclusively in the Hemato-
logy and Oncology Service, HC-UFPR were excluded as were
those who had biphenotypic leukemia, Fanconi anemia either
associated with myelodysplastic syndrome or in isolation,
those who were diagnosed before 2003 and those whose med-
ical records were not available. The ﬂowchart for selection of
the study population is detailed in Figure 1.
Data collection was based on the review of medical records
available from the Medical Archive Service (SAME), based on
the results of cytogenetic and immunophenotyping examina-
tions provided by the respective laboratories, as well as records
from the Hospital Epidemiology Service of HC-UFPR. Informa-
tion of interest was input on an Excel spreadsheet to facilitate
further analysis of the variables and to compile the results.
Data for clinical and epidemiological characterization of
the study population, such as gender, age at diagnosis, race,
family history of cancer, cytogenetics, the presence of the
t(15;17), complete remission rate after the ﬁrst induction, WBC
count at diagnosis and type of evolution (primary or sec-
ondary) were arranged in a table of absolute and relative
frequencies, with calculations performed using the Microsoft
Excel program.
Regarding the analysis of overall survival (OS) and EFS
of the patients, survival curves were constructed by the
Kaplan–Meier method, using the statistical program PRISM
(version 5.0). The deﬁnitions used for the calculation of
survival followed the revised recommendations of the Interna-
tional Working Group for therapeutic studies in acute myeloid
leukemia.13 The OS was deﬁned as the time interval between
the date of diagnosis and date of death or date of last follow-
up visit. The EFS was taken as the period between the date of
diagnosis and the date of relapse, induction failure or date of
death from any cause.
The curves of OS and EFS were also correlated with cer-
tain prognostic factors as reported in the literature, such as
age at diagnosis, FAB classiﬁcation, cytogenetics, WBC  count
11,12,14at diagnosis and evolution (primary and secondary).
A comparison of different curves was performed using the
log-rank test and differences with p-value < 0.05 being consid-
ered statistically signiﬁcant. The comparative analysis of the
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120 over 15-year-old patients with ICD of acute
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urves also included the Odds Ratio (OR) with respective 95%
onﬁdence intervals (95% CI).
Multivariate analyses of prognostic factors in relation to the
S, including cytogenetics, gender, age, WBC  count and type of
volution were performed using Cox regression analysis with
he SPSS 20.0 software.
The poor cytogenetic prognosis category included complex
aryotypes (two or more  unrelated abnormalities), monosomy
f chromosome 5, monosomy of chromosome 7, translo-
ations involving the 11q23 locus, and all deletions. The
ntermediate prognosis category was deﬁned as normal kar-
otype and trisomies of chromosomes 4, 8 and 21. The
ranslocations t(15;17), t(8;21) and inversions (16)/t(16;16) were
onsidered the only entities capable of predicting a favor-
ble prognosis. Other factors considered as poor prognosis
n the current study were age greater than 60, a WBC  count
t diagnosis over 30 × 109/L, secondary leukemia and the lack
f complete remission at ﬁrst induction. Complete remission
as considered to be the absence of signs and symptoms of
isease associated with normal complete blood count and less
han 5% blasts in bone marrow aspirate.
The categorization used was based on the French-
merican-British (FAB) group classiﬁcation, which comprises
ight subtypes of AML  (M0–M7) and is based on morpholog-
cal and cytochemical aspects.12 To compare survival curves,
atients were divided into three groups: Group I (FAB M0–M2),
roup II (FAB M3)  and Group III (FAB M4–M7).
esults
he ﬁnal study population was 98 individuals. Patients were
redominantly younger than 60 years old (81.6%), in the inter-
ediate cytogenetic risk group (40.8%), with ﬁrst complete
emission after induction chemotherapy (46.9%), white blood
ount less than 30 × 109/L (57.1%) and de novo leukemia (62.2%).lect the study population.
The mean age at diagnosis was 44.27 years. All clinical and
epidemiological features are listed in Table 1.
There was no statistically signiﬁcant difference when com-
paring the survival curves (Figure 2A) related to age for
patients above and below the cut-off determined for the study
population (median survival of 12.4 months for the group
aged less than or equal to 60 years versus 8.2 months for the
group older than 60 years; p-value = 0.2227; OR = 0.6676; 95%
CI = 0.3488–1.278). The median EFS (Figure 2B) was 10.7 months
for the younger group versus 7.3 months for the over 60-year
olds (p-value = 0.2448; OR = 0.6812; 95% CI = 0.3567–1.301). The
survival curve was not statistically signiﬁcant for the gender-
related SG with a median survival of 15.3 months for females
versus 26.8 months for the men  (p-value = 0.2756; OR = 0.7625;
95% CI = 0.4684–1.241).
OS curves for the type of evolution did not show any sta-
tistically signiﬁcant difference between the two  groups with
a median survival time for the primary leukemia group of
21.9 months versus 11.8 months for the group with secondary
leukemia (p-value = 0.1706; OR = 0.6824; 95% CI = 0.3951–1.179).
This study found a signiﬁcantly higher OS in the group with
WBC  count lower than 30 × 109/L at diagnosis (Figure 3A) with
a median survival time of 23.6 months versus 4.7 months for
the group with WBC  count of more  than 30 × 109/L at diag-
nosis (p-value = 0.0001; OR = 0.3651; 95% CI = 0.1403–0.5160). As
for EFS (Figure 3B), the group with leukocyte counts lower
than 30 × 109/L had a survival time of 19.3 months versus
3.0 months for the group with a leukocyte count of more
than 30 × 109/L at diagnosis (p-value = 0.0003; OR = 0.3042; 95%
CI = 0.1586–0.5834).
There was a signiﬁcantly longer OS for the subgroup
in which cytogenetics was associated with good prognosis
compared to the subgroup that included intermediate and
poor prognosis (median survival time: 97.7 versus 9.2
months; p-value = 0.0037; OR = 0.4239; 95% CI = 0.2374–0.7568 –
Figure 4A). A similar signiﬁcance was observed for EFS
24  rev bras hematol hemoter. 2 0 1 5;3 7(1):21–27
100
80
60
40
20
0
0 12 24 36 48 60 72 84 96 108
Time (months)
 0 12 24 36 48 60 72 84 96 108
Time (months)
Su
rv
iva
l (%
) P=.222 P=.244
Younger than 60 years
Older than 60 years
A 100
80
60
40
20
0
Su
rv
iva
l (%
)
B
Figure 2 – Age-related survival. (A) Overall survival and (B) event-free survival.
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Figure 3 – Survival in respect to white blood cell count. (A) Overall survival and (B) event-free survival.
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(97.7 versus 6.3 months; p-value = 0.0005; OR = 0.3591; 95%
CI = 0.2013–0.6407 – Figure 4B).
Some services sent incomplete results for immunopheno-
typing and myelogram analysis and so only 86% of the results
of the FAB classiﬁcation were obtained. According to this clas-
siﬁcation, 5% of the patients were in the M0  subgroup, 1% in
M1,  13% in M2,  31% in M3,  17% in M4,  11% in M5,  3% in M6 and
1% of the patients in M7.  The M3  subgroup had statistically
greater median OS and EFS as is shown in Figure 5A and B
(median OS of 23.5 months for M0,  M1,  M2;  97.7 for M3 and 7.4
months for M4,  M5,  M6  and M7;  p-value = 0.0288 and median
EFS of 15.2 months for M0,  M1,  M2;  97.7 for M3 and 6.1 months
for M4,  M5,  M6  and M7;  p-value = 0.0047).
Multivariate analysis was signiﬁcant for cytogenetics (p-
value = 0.015). Overall survival and (B) event-free survival.
In this analysis, 65.3% of patients died; 25% of the deaths
were due to disease progression. Bleeding was the second
most common cause of death, followed by infection and the
consequences of treatment.
Discussion
Information collected has signiﬁcant relevance as there is no
tradition of notiﬁcation or any surveillance system for AML.
Based on the absence of similar studies, we  sought to gather
data recorded in a referral service, HC-UFPR, during years to
identify situations in which morbidity and mortality might
be avoided. This study offers a fundamental methodological
arsenal to understand health problems and to develop future
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nalytical studies, despite the limitations inherent to retro-
pective studies.The data shows a slight predominance of males than
emales and an absolute majority of self-identiﬁed Caucasian
atients. Data available for Brazil is scarce, but data provided
Table 1 – Global clinical and epidemiological
characterization.
n %
Gender
Female 47 48
Male 51 52
Age
60 years or less 80 81.6
Over 60 years 18 18.4
Race
Caucasian 91 92.9
Non-Caucasian 7 7.1
Family cancer history
Present 40 40.8
Absent 39 39.8
Insufﬁcient information 19 19.4
Cytogenetics
Good prognosis 21 21.4
Intermediary prognosis 40 40.8
Poor prognosis 23 23.5
Insufﬁcient information 14 14.3
Translocation (15;17)
Present 17 17.3
Absent 81 82.7
Complete remission after ﬁrst induction
Present 46 46.9
Absent 43 43.9
Insufﬁcient information 9 9.2
White blood cell count
Lower than 30 × 109/L 56 57.1
Over than 30 × 109/L 26 26.6
Insufﬁcient information 16 16.3
Type of leukemia
Primary 61 62.2
Secondary 36 36.7
Insufﬁcient information 1 1.1cation. (A) Overall survival and (B) event-free survival.
by the American Cancer Society show that AML  is 1.7 times
more  prevalent in men  and slightly higher in the non-Hispanic
white population than other races.3 The high number of self-
identiﬁed Caucasian patients may be related to the equally
high prevalence of this race in the southern region of the coun-
try, where the research was conducted, or this is the kind
of information provided by patients who, for historical and
cultural reasons, tend to classify themselves as White.
The mean age at diagnosis was lower than that found in
the literature.3,15 As there is no clear deﬁnition of the cut-off
age to deﬁne the prognosis of AML, because of the statistical
signiﬁcance of the results, this study established the limit of 60
years to stratify the population into two groups. The disagree-
ment with the literature regarding the statistical signiﬁcance
for this factor may be related to the incorporation of AML M3,
prevalent in younger patients, with other subtypes of AML.3
The M3 subtype is a very peculiar form of leukemia and may
be considered a particular disease, both by the clinical char-
acteristics and by the good prognosis.9 However, due to the
limited number of subjects, this subtype was grouped with
other entities.
Older individuals had lower rates of complete remission,
OS and EFS when compared with younger patients. AML in
elderly is a biologically and clinically distinct entity. Based on
the analysis of molecular and cytogenetic data, it is known
that the leukemic cells in older patients are intrinsically resis-
tant to conventional chemotherapy. Due to comorbidities and
the poor reserve of stem cells in the bone marrow, older
adults do not tolerate myelosuppressive chemotherapy well
and there is a high treatment-related mortality rate and evo-
lution of the disease.3,15,16
There was no statistical signiﬁcance related to family his-
tory of cancer and the type of evolution (primary or secondary)
of the disease in the prognosis of these patients. Familial
occurrence is rare and its role in the development of the dis-
ease is uncertain, since the role of the type of evolution is
well established in the literature. History of prior myelodys-
plasia or myeloproliferative diseases is common (24–40% of
cases) in elderly patients with acute myeloid leukemia.17–19
The absence of any prognostic correlation may be related to
the higher proportion of young patients in the study popula-
tion.
Similar to the literature, the WBC  count was found to
be a signiﬁcant prognostic factor in the univariate analysis.
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The limit of 30 × 109/L was adopted due to the higher statis-
tical signiﬁcance found for this value in the current study,
although traditionally the decisive prognostic score is closer
to 20 × 109/L.20
This study found a correlation between higher WBC  counts
and reduced OS and EFS. One possible explanation for this
ﬁnding is that very high WBC  counts are associated with an
increased risk of tumor lysis syndrome and leukostasis. Both
these are considered oncologic emergencies and are able to
affect the prognosis of patients.21 In a multivariate analysis,
this factor did not show the same signiﬁcance, despite the
borderline value (p-value = 0.063).
Cytogenetics is a key point in the diagnosis, treatment and
prognosis of AML.22,23 In the present study, the survival curves
of patients with cytogenetics related to poor prognosis and
intermediate prognosis were grouped together with the prog-
nosis being poor due to overlapping.
Cytogenetics was statistically signiﬁcant both in univariate
analysis and in multivariate analysis, showing that, irrespec-
tive of other factors, this is an important prognostic factor.
Consistent with the literature, cytogenetics related to good
prognosis conferred a better survival for patients.22–24 There
was a signiﬁcant drop in the survival curve of patients with
cytogenetics related to poor prognosis; survival for this group
was close to 20% within the ﬁrst two years. The OS related
to good prognosis became stable at between 70% and 80% in
eight years of follow up. This data notoriously reveals the role
of cytogenetics in the prognosis of patients.
Currently, the classiﬁcation recommended for AML is one
established by the WHO  in 2008, which assesses the morpho-
logical, immunophenotypic and genetic combinations as well
as clinical manifestations of the disease.7,25 Since this is a ret-
rospective study and previous to WHO  deﬁnitions, this study
was based exclusively on the FAB classiﬁcation associated
with cytogenetics to establish subtypes.8
Acute promyelocytic leukemia (known as M3  in the FAB
classiﬁcation) is characterized by the translocation t(15;17)
and is regarded as a particular type of AML.9 In the present
study, similar to other publications, this kind of leukemia con-
ferred better survival rates than those observed for the other
subtypes.26–28
A higher death rate was observed related to the FAB M3
classiﬁcation in the ﬁrst days following diagnosis, probably
due to the high frequency of complications, such as dissemi-
nated intravascular coagulation (characteristic of this class of
AML). Subsequent deaths were mostly related to aggressive
treatment. Moreover the survival curve shows that patients
who  survived the ﬁrst stages of the illness and treatment had
higher survival rates than those of other subgroups. We must
stress that in this study the patients were grouped in respect
to the FAB classiﬁcation due to the overlap of the curves and
the size of the population studied.
ConclusionPrognostic factors signiﬁcantly inﬂuenced the survival of
patients, as well as guided treatment. Moreover, the outcomes
were consistent with the literature, adjusted for the popula-
tion in question. Clinical and epidemiological data provide
1r. 2 0 1 5;3 7(1):21–27
important tools for a possible development of surveillance
systems for AML, so that the necessities of the population
consulted at HC-UFPR are prioritized and effectively treated
by public health policies.
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